Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Infliximab

Brand: Remicade┬«, Inflectra┬«, Remsima┬«
NICE TA: 
Indication: Use in high risk patients for prevention of recurrence or upon recurrence of Crohn's Disease following surgery.
Disease category: Gastro-intestinal system
Commissioning responsibility: CCG
PbR excluded: Yes

Background

In patients at high risk of recurrence (e.g. more than one resection, or penetrating or fistulising disease), prophylaxis with thiopurine should be considered where appropriate. A biologic may be considered in these high risk patients upon recurrence, or if thiopurine treatment is not tolerated i.e RED colour classification. Note: Routine use of biologic agents to prevent recurrence of CD following surgery is not recommended.

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

Biosimilars of Infliximab (Version 1.1) (271.7 KiB)

Gastroenterology Biologics Pathway (Version 1.1) (355.6 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red